Ticagrelor Safety Profile & Adverse Events

Safety Profile Overview

Reversible P2Y12 inhibitor for ACS. Demonstrated superiority over clopidogrel in the PLATO trial. Dyspnea is a unique class-specific adverse effect.

Generic Name

ticagrelor

Brand Names

Brilinta

Therapeutic Class

P2Y12 Inhibitor

Manufacturer

AstraZeneca

What Pharma Signal Tracks for Ticagrelor

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Ticagrelor, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Ticagrelor products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Ticagrelor Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Ticagrelor.

curl "https://api.pharma-signal.com/drug/safety/ticagrelor" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Ticagrelor against other P2Y12 Inhibitor drugs, or explore the full manufacturer portfolio for AstraZeneca.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Ticagrelor ranks within P2Y12 Inhibitor on serious event rates.
Company portfolio risk — View all drugs from AstraZeneca with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.